


VALUING A CURE: ARE NEW APPROACHES NEEDED?


Mark Sculpher, PhD

*Professor of Health Economics
Centre for Health Economics
University of York, UK*


Complexity in evaluation




Complexity in evaluation




Cost-effectiveness and affordability




Cost-effectiveness and affordability




Cost-effectiveness and affordability



Cost-effectiveness and affordability



Cost-effectiveness and affordability




Estimating opportunity cost by budget impact




Lomas et al. *Value in Health*, 2018, 21:266-275

Evidential uncertainty – example of oncology




Example in oncology




Othus et al. Value in Health 2017;20:705-9


Decision uncertainty and its implications



Dealing with uncertainty



Should we value putative cures differently?



Conclusions

- Evaluation challenges not unique to 'cures'
- The toolkit exists, needs to be used
- Always need for further development
 - Survival modelling
 - Policy responses to uncertainty
 - Policy responses to high upfront costs

Thank you!

mark.sculpher@york.ac.uk



<https://www.york.ac.uk/che/>



[@MJSculpher](https://twitter.com/MJSculpher)